Showing results (101-110 of 125) with videos related to
Sort By:
Pageof 13
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 17, 2012
Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposureThomas Delate, Erin J Aiello Bowles, Roy Pardee, et al.The Oncologist|June 7, 2023
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)Rudolph M Navari, Jennifer Le-Rademacher, Fabrice Smieliauskas, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 4, 2013
Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancerDeanna S Cross, Alanna Kulchak Rahm, Tia L Kauffman, et al.Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|January 7, 2019
Racial/Ethnic Differences in Comprehension of Biospecimen Collection: a Nationwide University of Rochester Cancer Center NCI Community Oncology Research Program StudyMatthew Asare, Charles E Heckler, Eva Culakova, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)Madhur K Garg, Fengmin Zhao, Joseph A Sparano, et al.Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.Journal of the National Cancer Institute|September 6, 2012
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort studyErin J Aiello Bowles, Robert Wellman, Heather Spencer Feigelson, et al.NPJ Precision Oncology|January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinomaSandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 14, 2025
Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC PathwayZhi Wen, Yidan Wang, Kathryn C Fox, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 17, 2012
KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settingsJennifer Webster, Tia L Kauffman, Heather Spencer Feigelson, et al.Pageof 13